格隆汇8月8日丨贝瑞基因(000710.SZ)公布，根据北京贝瑞和康生物技术有限公司（简称"贝瑞和康"）业 务规模发展及运营的需要，成都市贝瑞和康基因技术股份有限公司全资子公司贝瑞和康拟与自然人李巍 先生在河南省郑州市投资设立控股子公司，子公司拟注册名称为河南壹元童康基因科技有限公司（简 称"壹元童康""合资公司"）（最终名称以市场监督管理部门核定登记为准），注册资本为100万元人民 币。其中，贝瑞和康以自有资金认缴出资60万元，持股比例为60%；自然人李巍先生以自有资金认缴出 资40万元，持股比例为40%。 本次子公司对外投资设立合资公司，首期注册资本100万元，主要用于场地租金和初期人员费用，合资 公司的产品及其相关服务（包含基因测序和AI智能体服务等），主要通过向成都市贝瑞和康基因技术 股份有限公司及其下属主体采购获得。合资公司将根据业务进展情况，通过注册资本增资等方式，扩充 合资公司经营资金。如合资公司未来经营情况符合各方预期，预计注册资本不低于5,000万元。 ...

贝瑞基因（000710）(000710.SZ)公告，公司全资子公司贝瑞和康拟与自然人李巍先生在河南省郑州市 投资设立控股子公司，子公司拟注册名称为河南壹元童康基因科技有限公司(简称"壹元童康")，注册资 本为100万元。其中，贝瑞和康以自有资金认缴出资60万元，持股比例为60%;自然人李巍先生以自有资 金认缴出资40万元，持股比例为40%。该合资公司计划以公共医疗机构和临床医疗企业紧密合作的形 式，在河南等重点区域开展新生儿及儿童基因病一体化检测服务。 本次注册资金主要用于场地租金和初期人员费用，合资公司的产品及其相关服务(包含基因测序和AI智 能体服务等)，主要通过向成都市贝瑞和康基因技术股份有限公司及其下属主体采购获得。 值得一提的是，合资公司将根据业务进展情况，通过注册资本增资等方式，扩充合资公司经营资金。如 合资公司未来经营情况符合各方预期，预计注册资本不低于5000万元。 ...

Investment Rating - The industry rating is "Outperform the Market" indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 to 12 months [79]. Core Insights - The report highlights a significant increase in bidding data for medical equipment, with monthly bidding amounts showing year-on-year growth rates ranging from 41% to 113% from December 2024 to May 2025, suggesting a robust demand recovery [4][17]. - The report emphasizes the strong performance of innovative drugs, with companies like China Biopharma and Rongchang Bio continuing to see positive developments, supported by government policies optimizing drug procurement [5][41]. - The medical device sector is expected to experience a turning point in financial reporting in Q2 and Q3 2025, as the effects of increased bidding data begin to reflect in company revenues [4][26]. Summary by Sections 1. Weekly Performance Review - The CITIC Medical Index rose by 1.5% during the week of June 9-13, 2025, outperforming the CSI 300 Index by 1.8 percentage points, ranking third among CITIC's primary industry classifications [3][41]. - The top five performing stocks for the week included Yiming Pharmaceutical (+38.49%), Saiseng Pharmaceutical (+36.35%), and Aoyang Health (+35.01%) [59]. 2. Equipment Bidding Data - Bidding amounts for medical equipment have shown a consistent increase, with May 2025 seeing a 69% year-on-year growth, indicating a strong recovery in demand [4][17]. - The report predicts that the financial results for companies involved in equipment installation will begin to reflect this demand surge in Q2 2025, while inventory companies may see performance improvements by Q3 2025 [4][26]. 3. Mid to Long-term Investment Strategy - The report suggests focusing on three main themes: innovation, recovery, and policy support. It highlights the potential for innovative drugs and medical devices to drive growth, particularly in companies with strong international competitiveness [5][6]. - Specific companies to watch include Union Medical, Shanhai Mountain, and Mindray Medical, which are expected to benefit from the ongoing recovery in bidding data and demand [4][6][27].

Core Viewpoint - The rapid integration of internet healthcare and artificial intelligence (AI) is driving significant interest and investment in AI healthcare stocks, particularly in the Hong Kong market, where related stocks have seen substantial price increases [1][2][3]. Group 1: Market Performance - The Hong Kong healthcare index has been rising, benefiting AI healthcare stocks, with notable price increases such as Health Road's stock rising by 5.57% and a total increase of 49.13% over three trading days since June 2 [1]. - Other companies like Meili Tianyuan Medical and CloudTop New Drug have also experienced significant stock price increases, with Meili Tianyuan's stock rising by 34.25% and CloudTop New Drug by 5.16% [1]. - The performance of AI healthcare stocks has positively impacted public fund products, attracting substantial institutional investment despite high valuations [1][2]. Group 2: Fund Strategies - Many pharmaceutical funds are shifting their top holdings from innovative drug stocks to AI healthcare companies, with examples including Silver Hua Fund's top three holdings now being AI healthcare firms [2]. - Even bond-focused public funds are showing interest in high-volatility AI healthcare stocks, indicating a broadening appeal across different fund types [2]. - The Hang Seng Medical ETF has seen a 34.69% increase since April 9, reflecting the growing interest in AI healthcare investments [2]. Group 3: Investment Opportunities - Investment opportunities in the AI healthcare sector are concentrated in three main areas: AI drug development, AI medical applications, and data production and application [3][4]. - AI technology is expected to enhance the efficiency of new drug development, with several AI-assisted drugs entering clinical validation stages [3]. - The integration of AI in traditional medical practices is anticipated to improve diagnostic efficiency and capabilities, while also reducing costs in drug development [4]. Group 4: Industry Trends - The AI healthcare sector is experiencing a clear trend towards commercialization, with significant orders in health management, clinical decision support, imaging diagnostics, and drug development [5]. - The Chinese government is promoting AI applications in the pharmaceutical industry, supporting the establishment of innovative platforms and pilot projects across the entire pharmaceutical value chain [4][5]. - Companies are actively recruiting talent with expertise in both medicine and AI to enhance their capabilities in clinical decision-making and drug development [5].